
Cabenuva: Change in Dosing Frequency



Cabenuva, a 2-drug co-packaged product of cabotegravir (CAB LA), an HIV-1 INSTI, and rilpivirine (RPV LA), an HIV-1 NNRTI, is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.¹⁻²

Dosing Recommendations When Switching from Monthly to Every-2-Month Dosing¹⁻²



CAB LA Single IM injection (400 mg, 2 mL) RPV LA Single IM injection (600 mg, 2 mL)



CAB LA
Single IM
injection
(600 mg, 3 mL)

RPV LA Single IM injection (900 mg, 3 mL)



Administer 1 month after the last monthly continuation injections and then every 2 months thereafter.

Dosing Recommendations When Switching from Every-2-Month to Monthly Dosing¹⁻²

Every-2-Month Dosing of *Cabenuva:* (continuation injection schedule)

CAB LA
Single IM
injection
(600 mg, 3 mL)

RPV LA Single IM injection (900 mg, 3 mL)



Monthly Dosing of *Cabenuva:* (continuation injection schedule)

CAB LA
Single IM
injection
(400 mg, 2 mL)

RPV LA Single IM injection (600 mg, 2 mL)



Administer **2 months** after the last every-2-month continuation injection and then **monthly** thereafter.



Both (CAB LA and RPV LA) injections should be administered as **IM injections** at separate gluteal injection sites (on opposite sides or at least 2 cm apart) during the same visit.¹⁻²

Important safety information can be found in the Prescribing Information and can also be accessed at Our HIV Medicines.

For more information







Some information contained in this response may not be included in the approved Prescribing information. This response is not intended to offer recommendations for administering this product in a manner inconsistent with its approved labeling. In order for ViiV Healthcare to monitor the safety of our products, we encourage healthcare professionals to report adverse events or suspected overdoses to the company at 877–844–8872. Please consult the attached Prescribing Information. This response was developed according to the principles of evidence-based medicine and, therefore, references may not be all-inclusive.

Abbreviations: CAB LA = long-acting cabotegravir; HIV-1 = human immunodeficiency virus type 1; IM = intramuscular; INSTI = integrase strand transfer inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; RPV LA = long-acting rilpivirine; RNA = ribonucleic acid.

Reference: 1. ViiV Healthcare Local Label; 2. ViiV Healthcare. Global Data Sheet for Cabotegravir. Version 06. January 24, 2022.